8-K: INmune Bio Amends Executive Compensation Agreements

INmune Bio Inc. filed an 8-K to correct errors in the employment agreements for its President and CEO, David J. Moss, and CFO, Cory Ellspermann, regarding base salaries and stock option grants.

Summary

• INmune Bio Inc. (the Company) entered into amendments to employment agreements for its President and CEO, David J. Moss, and CFO, Cory Ellspermann, on December 2, 2025.
• The amendments were made to correct errors in the original agreements dated November 26, 2025.
• David J. Moss's base salary was restated to $454,000 per annum.
• Mr. Moss's stock option grant was restated to 750,000 shares under the Second Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan.
• Cory Ellspermann's base salary was restated to $240,000 per annum.
• The amendments are effective retroactively as of the original effective date of the employment agreements.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily addresses administrative corrections to executive employment agreements, which is a routine corporate action and does not reflect operational performance or strategic shifts.

Positives

• The company is proactively correcting administrative errors in executive employment agreements, demonstrating attention to detail in corporate governance.

Negatives

• The initial existence of errors in executive employment agreements could suggest minor administrative oversight, though promptly corrected.

Future Outlook

This filing does not contain any forward-looking statements or guidance beyond the corrected terms of the executive employment agreements.

Management Comments

• The amendments are intended solely to correct errors in the original employment agreements.
• The amendments shall be deemed effective retroactively as of the original effective date of the agreements.

Industry Context

This announcement is an internal corporate governance and compensation matter, not directly indicative of broader industry trends or competitive landscape shifts. It reflects standard administrative adjustments within a publicly traded biotechnology company.

Comparison to Industry Standards

• The filing does not provide sufficient detail on executive compensation structures or peer group comparisons to assess against global industry benchmarks.
• Executive compensation packages, including base salary and stock options, are typically benchmarked against companies of similar size, stage of development, and industry (e.g., biotechnology, pharmaceuticals) to ensure competitiveness and alignment with shareholder interests. Specific comparable companies or projects are not mentioned in this filing.

Corporate Governance

Related Party Transactions

• Amendments to employment agreements with the President and CEO, David J. Moss, and the CFO, Cory Ellspermann, constitute related party transactions, which are standard for executive compensation.

Stakeholder Impact

• Shareholders: The correction of the CEO's stock option grant ensures accurate disclosure of potential dilution and executive incentives, which is important for shareholder transparency.
• Employees: No direct impact on general employees is indicated by these executive compensation adjustments.

Key Dates

Keywords

INmune Bio, INMB, executive compensation, employment agreement, CEO salary, CFO salary, stock options, corporate governance, SEC filing, Form 8-K